Abstract. Calcineurin inhibitors (CNI) are an important component of most immunosuppressive protocols utilized in renal transplantation. Both CNI available (cyclosporine and tacrolimus) have been used for many years. Studies comparing the efficacy of these two agents in terms of long-term graft or patient survival have thus far failed to show an advantage for either agent. This failure to show a difference could possibly be due to underpowering of clinical trials. The authors used the SRTR database to analyze 5-yr graft survival of the microemulsion formulation of cyclosporine (Neoral) as compared with tacrolimus. To minimize the donor variability and bias, a paired kidney analysis was used. Deceased donors from the years 1995-2002 were analyzed from the SRTR database. All paired kidneys during this period, where one kidney was allocated to a patient receiving initial Neoral therapy and its mate allocated to a patient receiving initial tacrolimus therapy were evaluated. Multivariate and univariate analysis were performed. Univariate analysis demonstrated equivalent graft survival for Neoral compared with tacrolimus (66.9% versus 65.9%, respectively). Multivariate analysis could not demonstrate a difference in risk for 5-yr patient survival or graft loss. Renal function was superior for tacrolimus at all time points, whereas the slope of 1/Cr over time did not differ for the two agents. In this paired kidney analysis, no difference in 5-yr renal allograft survival could be found between the two agents. Renal function was superior in the patients receiving initial tacrolimus therapy; however, slope of 1/Cr did not differ between the agents.
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Calcineurin inhibitor (CNI) therapy remains an important component of current immunosuppressive protocols utilized in renal transplantation (1) . Both cyclosporine and tacrolimus are used with excellent results (2-4). These two immunosuppressive agents are thought to broadly exert their immunosuppression action by similar mechanisms (5, 6) . However, they do differ in chemical structure, binding proteins, and toxicity profiles (7) (8) (9) (10) (11) . Studies have been undertaken to compare the efficacy of these two agents. The majority of these studies have demonstrated lower acute rejection rates in regimens utilizing tacrolimus versus cyclosporine, even when the newer microemulsion formulation of cyclosporine was utilized (12) (13) (14) (15) (16) (17) . Despite this decrease in acute rejection rate, no statistical difference could be demonstrated between the agents in 1-yr and 3-yr graft survival in these studies. A recent prospective study noted that a survival benefit of tacrolimus could be found when crossover was considered as an end point. However, it is important to note that even in this study the intention-to-treat analysis could not demonstrate a difference in 5-yr graft survival (17) . Despite the lack of a statistical difference in graft survival, this study did show a lower creatinine and presumed better renal function in the group of patients receiving tacrolimus.
It is possible that the failure of these clinical studies to statistically demonstrate an improvement in graft survival was related to the number of patients enrolled and the relatively short follow-up period assessed in these studies.
Registry analysis has the advantage of providing sufficient numbers to adequately power an analysis for relatively rare endpoints (e.g., Graft survival). However, registry analysis cannot always account for subtle and hidden selection bias. To diminish any donor bias and to attempt to provide an analysis that would minimize hidden bias, we utilized the Scientific Registry of Transplant Recipients (SRTR) and compared longterm graft survival and renal function in paired deceased donor kidneys where one kidney was allocated to a patient placed on Neoral therapy and the other mate kidney allocated to a patient placed on tacrolimus therapy.
Materials and Methods
To examine the relative impact of Neoral and Prograf specifically, a paired-kidney analysis was conducted. Deceased donors from 1995-2002 who allocated one kidney to a first transplant recipient receiving Neoral therapy at baseline and one kidney to a first transplant recipient receiving Prograf therapy at baseline were identified, and outcomes were measured. Paired kidney donations were identified by use of a donor identification code provided in the SRTR database. This type of analysis excluded donor characteristic biases and era effects as confounding factors and allowed us to examine the relative impact of the inhibitors independently of these. There were 3070 observations in each arm of the analyses, and we analyzed the calcineurin inhibitor effect on survival utilizing univariate Kaplan-Meier plots as well as multivariate Cox models, adjusted for potential confounding factors.
Covariates in the Cox models were assessed for adherence to the proportional hazard assumption, and univariate analyses were tested using log-rank tests. For the purpose of this study, medication regimen was defined as initial medication at discharge from the hospital from information immediately after transplantation. Patients with multiple listings of calcineurin inhibitor medications were eliminated from the analysis. The Efron method was used for tied values in the Cox models.
To investigate the impact of the calcineurin inhibitor medication on renal function, we examined the reported creatinine levels at the given follow-up periods. Inverse serum creatinine (SCr)
Ϫ1 was utilized for tests involving renal function. To test for any difference in (SCr)
Ϫ1 , we conducted a t test paired by the original donor. In addition to examining the magnitude of renal function, we also analyzed the change in renal function over time by assessing the percent change in inverse creatinine from a 6-mo follow-up period to subsequent follow-up periods.
To further investigate the impact of the inhibitor medication in the paired kidney subjects, we examined the rates and presence of acute rejection in the posttransplant follow-up period. Acute rejection was indicated by reported acute rejection or treatment for acute rejection in the follow-up forms. We examined the rates of acute rejection by medication regimen along with performing a multivariate logistic regression to assess the effect of the inhibitor medication on acute regression in the first year posttransplant adjusted for other potential confounding factors. In the case of the logistic regression, observations were included that had a minimum of 1 yr theoretical follow-up time. All analyses were conducted with SAS software (version 8.02; SAS Institute, Cary, NC).
Results
Demographic and recipient treatment information from the analysis are displayed in Table 1 . Patients receiving Neoral at baseline had slightly higher recipient ages (49 yr versus 47 yr), shorter waiting times on dialysis (37 mo versus 43 mo), higher proportion of males (63% versus 57%), more patients using MMF antiproliferative medication (79% versus 77%), and a lower proportion of African-American patients (25% versus 29%) relative to recipients on Prograf at baseline.
The Kaplan-Meier plot for overall graft survival revealed very similar survival curves (log-rank P ϭ 0.4663), 5-yr graft survival was 66.9% and 65.9%, respectively, for Neoral and Prograf. Death-censored graft survival univariate results (see Figure 1 ) were very similar (log-rank P ϭ 0.8309) and had similar 5-yr rates (Neoral, 77.7%; Prograf, 78.3%). Results were also not statistically significant for the outcome of patient survival (log-rank P ϭ 0.1767), with 5-yr patient survival equal to 82.6% in the Neoral group and 80.2% in the Prograf group. To address the degree of crossover of inhibitor medication regiments, we also examined the registry for follow-up information. At the 6-mo follow-up interval, recipients who were on Neoral at baseline were reported (where 6-mo forms were present) to have remained on Neoral at a rate of 87.2%, while the Prograf baseline group reported 91.8% remaining on Prograf. At 1 yr, the proportion of those remaining on their baseline calcineurin inhibitor medication (where the 1-yr follow-up form were present) was 83.1% in the Neoral group and 91.7% in the Prograf group. Of the 3070 recipient pairs, 674 (22.0%) received treatment at the same center, outcomes were not statistically different between these pairs and pairs (78.0%) of patients receiving treatment at different centers.
We also examined the effect of the calcineurin inhibitor medication in multivariate Cox models. The adjusted overall graft survival (Figure 2 ) displayed very similar survival curves, including 5-yr survival rates of 69.4 and 69.0 for Neoral and Prograf, respectively. The models were adjusted for induction and antiproliferative therapies, cold ischemia time, PRA level, HLA-A, B, and DR mismatches, recipient age, recipient gender, recipient ethnicity, waiting time on dialysis, and primary diagnosis. The hazard estimates for Neoral (with Prograf as the reference group) for overall graft loss (see Table 2 ) and death censored graft loss were 0.979 (0.861 to 1.112) and 1.097 (0.925 to 1.302), respectively. The 6-mo inverse creatinine values were statistically significantly (P Ͻ 0.0001) lower in the Prograf arm than the Neoral from a paired t test for a mean difference. While the magnitude of the renal function was statistically different at 6 mo, the change in renal function (as measured by inverse creatinine) from 6 mo to 1, 2, 3, 4, and 5 yr follow-up periods were not significantly different between the calcineurin inhibitor groups. The overall mean levels and 95% CI of serum creatinine levels at the applicable follow-up periods are displayed Figure 3 . The creatinine levels and their respective SD can be seen on Table  3 . The rate of any report of acute rejection within 1 yr posttransplant for the medication regiments of Neoral/AZA, Neoral/MMF, Prograf/AZA, and Prograf/MMF were 27.2%, 21.5%, 24.6%, and 21.9%, respectively. The multivariate logistic model did not find any significant effect of the inhibitor medication on the presence of acute rejection in the first year posttransplant, the odds ratio for Neoral (with Prograf as reference) equal to 0.991 (0.867 to 1.132).
Discussion
Our study failed to demonstrate a significant difference in 5-yr graft survival between patients receiving initial tacrolimus versus those receiving Neoral as initial therapy. Baseline recipient demographics were similar in both groups; as both the univariate and multivariate analysis were consistent in a lack of difference, it is unlikely that this lack of difference could be attributed to any major demographic differences in the respec- tive groups. As this was a paired kidney analysis by design, no differences in donor characteristics would be expected. As the multivariate analysis corrected for concurrent immunosuppressive medication and as the percent of patients receiving induction therapy or MMF therapy did not differ to any great extent, it is highly unlikely that this played a role in these findings. Opposed to the recent clinical trials, we could find no statistical difference in acute rejection rates between the agents. It is highly unlikely that reporting of acute rejection is systematically over reported for one agent as opposed to the other. Also as the secular trend is for both greater tacrolimus utilization and lower acute rejection rates in the most proximate years, this finding is unlikely due to either an era effect or a systematic bias. In addition, as this lack of difference was confirmed by the multivariate analysis, we feel it is highly unlikely to be due to differences in demographic characteristics. As dose of medications are not known, it is possible that this contrary finding may be due to dosing differences other than what was proscribed in clinical trials.
In essence, this analysis is similar to an intention-to-treat analysis in that patients were assigned to each group according to the agent they were initially given. We felt this type of analysis would help avoid selection bias, as reasons for switching are not available. It is important to note that the number of patients who switched off Neoral at 1 yr was 16.9%, while it was 8.3% for tacrolimus. It is possible that this might account for our failure to detect a difference in survival in both groups. However, given these numbers, it is mathematically unlikely that this would have influenced these results. As acute rejection rates were equivalent, it is also unlikely that a switch secondary to this reason would significantly alter these results. Still, as the effect of switching cannot be assessed by this type of analysis, we would like to make clear that this study can only address the issue of initial therapy.
In terms of renal function, initial tacrolimus therapy demonstrated improved renal function over patients who received Neoral as initial therapy. This was a paired kidney analyses; it is therefore extremely unlikely that this difference reflected differences in any donor variables. This difference in serum creatinine was statistically significant even in the earliest time period measurement, and was sustained throughout the 5-yr period. On the other hand, the slope of 1/Cr or change in renal function did not appear to be different between the two agents. This is similar to findings noted in clinical trials (16 -18) . This improved renal function early, however, did not translate in to improved graft survival at 5 yr. Without a direct measure of renal function, it is possible that the lower creatinine observed in patients who received tacrolimus might be reflective of a decrease in muscle mass in this group compared with patients receiving Neoral therapy. As a difference in muscle growth or catabolism has not been seen in previous studies comparing these two agents, we feel it is unlikely to explain the differences in creatinine values observed in this study.
In summary, in this paired kidney analysis, we could find no evidence for any difference in 5-yr graft survival for patients initiated on either tacrolimus or Neoral therapy. Renal function was superior in the Tacrolimus group; however, there was no difference in the slope of 1/Cr between the agents. Whether initial therapy with either calcineurin inhibitor is associated with improvement in even longer-term graft survival will need to be assessed by future studies.
